RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
Norman Shippee joins RSI
RSI is pleased to announce that Norman Shippee recently joined the team as a Climate and Applications Specialist. Dr. Shippee earned his PhD at the…
Emma Hartnett receives Chauncey Starr Distinguished Young Risk Analyst Award
The Society for Risk Analysis (SRA) Council has awarded Dr. Hartnett the 2016 Chauncey Starr Distinguished Young Risk Analyst Award. The Chauncey Starr Distinguished Young…
Dr. Donald R. Mattison co-authors: Adult Utilization of Psychiatric Drugs
Because there is limited information available concerning the use of psychiatric drugs among the US adult population, Drs Moore and Mattison sought to characterize adult…
RSI launches game-changing climate app
RSI launched the Climate Change Hazards Information Portal (CCHIP).